Jamie is a Vice President with OMX Ventures. Prior to OMX Jamie developed deep experience in early-stage Biotech investing and company creation while working on the investment team at RA Capital.  In that role he served on the board of Enara Bio, Avilar Therapeutics, and Endor Therapeutics. Before joining RA, he was a Director at Boehringer Ingelheim Venture Fund and served as a Board Director of both Tilos Therapeutics (acquired by Merck & Co.) and Rewind Therapeutics. He holds a B.S. in Biology with a minor in Chemistry from Hillsdale College and a Ph.D. in Molecular and Cellular Biology from the University of Notre Dame.